The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Sep. 19, 7:21 AM

Slide #25. Athenex, Inc. Secondary Offering

Company: Athenex, Inc. (NASDAQ:ATNX)
Date announced: 9/8/2020
Shares Offered: 10,000,000
Date of Pricing: 9/10/2020
Price Per Share: $11.00
Secondary Offering Details: Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it intends to offer and sell, subject to market conditions, 10,000,000 shares of its common stock in an underwritten public offering. In addition, Athenex expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 9/10- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds to Athenex from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be $110 million. In addition, Athenex has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 14, 2020, subject to customary closing conditions.

Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Co. has three platforms: its Oncology Innovation Platform, dedicated to the research and development of its proprietary drugs; its Commercial Platform, focused on the sales and marketing of its specialty drugs and the market development of its proprietary drugs; and its Global Supply Chain Platform, dedicated to providing a supply of active pharmaceutical ingredients for its clinical and commercial efforts. Co.'s clinical pipeline includes: Orascovery, Src Kinase inhibition, T-cell Receptor-engineered T-cells, and arginine deprivation therapy.

ATNX SEC Filing Email Alerts Service

Open the ATNX Page at The Online Investor »

Company Name: 
Athenex Inc
Website: 
www.athenex.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding ATNX: 
24
Total Market Value Held by ETFs: 
$90.66M
Total Market Capitalization: 
$1.07B
% of Market Cap. Held by ETFs: 
8.50%
 

Open the ATNX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
98th percentile
(ranked higher than approx. 98% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.